Intranasal Oxytocin for the Treatment of Children and Adolescents with Autism Spectrum Disorders (ASD)
Medication Clinical Trials
This is a study investigating whether Intranasal Oxytocin (Syntocinon®) helps to improve symptoms of Autism Spectrum Disorder, specifically social functioning (e.g. learning how to talk to others, making friends) and repetitive behaviours.
Who can participate
10 years to 17 years of age with an autism spectrum disorder (ASD, autism, PDD-NOS, or Asperger’s syndrome)
24 Week (6 Month) clinical trial intervention study, which involves taking a nasal spray every day for three months, with a follow up visit three months later.
You and your child will first be asked to come in for a screening session; through talking with you and completing some assessments we will determine if your child meets eligibility criteria. If your child meets criteria, then you will then receive either Oxytocin (Syntocinon®) or placebo. Visits will take place every two weeks while your child is taking the drug or placebo.
This study also has an optional continuation part, which means that if you were given placebo, you will be able to take Oxytocin (Syntocinon®) at the end of the six months. The same tests and procedures will be followed that were followed during the main study.
Interested in participating
Recruitment is closed at this time.
U.S. Department of Defense